How to Submit a Perfect Safety, Toxicology and Clinical Data Package at FSSAI

An Expert’s Overview for Importers, and Regulatory Professionals

By Dr. Ashwini Kumar

Founder & CEO, CE Group of Companies  |  Forbes Business Council Member

Regulatory Affairs Expert | Clinical Trials Advisor | Medtech & Food Regulatory Consultant

The Section That Decides Your Application

In fifteen years of guiding food and Nutraceutical companies through FSSAI’s Non-Specified Food (NSF) approval process, I have reviewed hundreds of dossiers. The pattern is consistent: the administrative documents are usually in order. The Certificate of Analysis is usually submitted. The international regulatory status is usually documented.

The Section D — Safety, Toxicology, and Clinical Data — is where applications are won or lost.

It is the section where most are least prepared. It is the section where FSSAI’s Scientific Panels spend the most time. And it is the section where the gap between what applicants submit and what the Panel needs to conduct a credible risk assessment is widest.

This article addresses that gap directly.

What Does the FSSAI Scientific Panel Look For?

When reviewing a Non-Specified Food (NSF) application, the FSSAI Scientific Panel evaluates whether the ingredient is safe for its intended use. A well-prepared safety dossier should clearly answer the following questions:

• Can the ingredient cause any harmful effects? – Identify any known safety concerns based on available scientific evidence.
• At what level is the ingredient considered safe? – Summarise the available toxicological and clinical data, including safe intake levels where applicable.
• How much of the ingredient is likely to be consumed? – Estimate the expected daily intake based on the proposed use and recommended serving size.
• Does the available evidence support its safe use? – Demonstrate that the proposed level of consumption is supported by the overall safety data.

A clear and well-organised dossier helps the Scientific Panel review the available evidence more efficiently. It should present the scientific data in a logical manner, explain any limitations where relevant, and provide a well-supported conclusion on the safety of the ingredient under the proposed conditions of use.

Genotoxicity: The Non-Negotiable Foundation

Genotoxicity assessment is an important part of the safety evaluation for many Non-Specified Food (NSF) ingredients. It helps determine whether an ingredient has the potential to damage genetic material (DNA), which is a key consideration in assessing its safety for human consumption.

A well-documented genotoxicity assessment strengthens the overall safety package and supports a more robust scientific review.

Clinical Safety Data — The Human Evidence the Panel Prioritises

Animal toxicology data establishes the theoretical safety envelope. Human clinical data validates whether that envelope holds in actual human use. For ingredients that have been in global commercial use for several years, the clinical safety database is often the strongest and most persuasive element of the dossier.

Building Your Clinical Safety Evidence Package

Do not submit PDFs of clinical papers and expect the Panel to extract the safety data. Build a dedicated clinical safety summary document that includes:

• A tabulated summary of all clinical studies — study design, n, duration, dose, population, safety outcomes, adverse events, serious adverse events, withdrawals
• Explicit calculation of the proportion of participants experiencing adverse events versus controls
• Any dose-dependent adverse event signals — acknowledged and mechanistically explained
• Post-market safety surveillance data if the ingredient has been commercially available — spontaneous adverse event report.
• Relevant safety communications or regulatory observations issued by recognized international authorities, together with an explanation of their relevance to the proposed ingredient and intended use.

Critical principle: Transparency builds credibility with the Panel. Dossiers that present only favourable data and omit known adverse signals are viewed with suspicion. A dossier that acknowledges a known adverse event profile, explains it mechanistically, and demonstrates that it does not occur at the proposed Indian dosage is far more persuasive than one that pretends the adverse event literature does not exist.

Allergenicity Assessment – An Important Safety Consideration

Allergenicity is often overlooked but is an important part of the safety assessment for novel proteins, insect-derived ingredients, algae, mycoprotein, and novel botanical ingredients.

For plant-derived ingredients, such as quercetin, fisetin, and spermidine, any potential allergenicity or cross-reactivity with known food allergens should be assessed to support the FSSAI safety evaluation.

Safety Executive Summary – A Key Part of the Safety Dossier

The Safety Executive Summary provides a clear overview of the scientific evidence supporting the safety of the ingredient. It helps present the available data in a logical and easy-to-review format.

A well-prepared Safety Executive Summary should include:

• A brief description of the ingredient, its proposed use, and daily intake.
• A summary of the available genotoxicity and toxicology data.
• Safe intake levels (such as NOAEL or ADI), where available.
• Estimated daily intake based on the proposed use.
• A summary of available clinical safety studies.
• Any known safety concerns and how they have been addressed.
• A clear conclusion supporting the safe use of the ingredient under the proposed conditions.

A well-structured summary helps present the safety evidence clearly and supports the scientific review of the FSSAI NSF application.

Responding to Scientific Panel Queries

Queries from the FSSAI Scientific Panel are a normal part of the review process. Timely, complete, and well-supported responses help ensure a smoother evaluation.

When responding to queries:

• Reply within the prescribed timeline.
• Address each query clearly and provide supporting scientific evidence.
• If requested data are unavailable, provide a scientific justification along with the best available supporting evidence.
• Submit responses in a structured format with relevant supporting documents.

How CliniExperts Can Help

CliniExperts brings together regulatory affairs expertise, clinical research capability, and biostatistical support under one roof — making us uniquely positioned to manage the most technically demanding component of the NSF dossier process. Our Safety, Toxicology, and Clinical Data services include:

• Pre-filing safety data gap analysis — written assessment of what data you have and what you need before the ₹50,000 fee is committed
• Tiered safety assessment determination — expert recommendation on appropriate study requirements for your specific ingredient
• Genotoxicity study design and GLP lab coordination — study protocol review, lab selection, data review
• NOAEL-to-ADI calculation with uncertainty factor justification
• Indian EDI modelling using NNMB/ICMR dietary data
• Safety margin calculation and risk characterisation narrative
• Clinical safety database compilation — systematic literature review, evidence grading, clinical safety summary document
• Allergenicity assessment — sequence homology analysis, cross-reactivity evaluation
• Safety Executive Summary authorship — scientific narrative written by our MD-qualified regulatory team
• Scientific Panel query response management — from query analysis to final response document

 

The difference between a dossier that clears FSSAI’s Scientific Panel in 12 months and one that stalls for 24 is almost always the quality of the Section D safety data package. If you are planning an NSF application and want an expert assessment of your current safety data position, we are here to help.